Trial record 1 of 1 for:
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06203210 |
|
Recruitment Status :
Not yet recruiting
First Posted : January 12, 2024
Last Update Posted : April 22, 2024
|
Sponsor:
Daiichi Sankyo
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Daiichi Sankyo
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2027 |
| Estimated Study Completion Date : | February 22, 2029 |